IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baraldo, K.
Right arrow Articles by Del Giudice, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baraldo, K.
Right arrow Articles by Del Giudice, G.
Infection and Immunity, August 2004, p. 4884-4887, Vol. 72, No. 8
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.8.4884-4887.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

N19 Polyepitope as a Carrier for Enhanced Immunogenicity and Protective Efficacy of Meningococcal Conjugate Vaccines

Karin Baraldo,1 Elena Mori,1 Antonella Bartoloni,2 Roberto Petracca,1 Aldo Giannozzi,2 Francesco Norelli,2 Rino Rappuoli,1 Guido Grandi,1 and Giuseppe Del Giudice1*

Research Center,1 Technology Development, Chiron Vaccines, 53100 Siena, Italy2

Received 20 February 2004/ Returned for modification 1 April 2004/ Accepted 24 April 2004

N19, a string of human universal CD4 T-cell epitopes from various pathogen-derived antigens, was shown to exert a stronger carrier effect than CRM197 for the induction of anti-group C Neisseria meningitidis capsular polysaccharide (MenC), after immunization of mice with various dosages of N19-MenC or CRM-MenC conjugate vaccines. After two immunizations, the N19-based construct induced anti-MenC antibody and protective bactericidal antibody titers higher than those induced by three doses of the CRM-MenC conjugate and required lower amounts of conjugate. N19-based conjugates are superior to CRM-based conjugates to induce protective immune responses to MenC conjugates.

* Corresponding author. Mailing address: Research Center, Chiron Vaccines, via Fiorentina 1, 53100 Siena, Italy. Phone: 39-0577-243261. Fax: 39-0577-243564. E-mail: Giuseppe_Del_Giudice{at}Chiron.it.

Editor: J. T. Barbieri

Infection and Immunity, August 2004, p. 4884-4887, Vol. 72, No. 8
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.8.4884-4887.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2004 by the American Society for Microbiology. All rights reserved.